List of all relevant publications by Horizon scientists and academic collaborators:
Use of isogenic human cancer cells for high-throughput screening and drug discovery
Nat Biotechnol. 2001 Oct; 19(10): 940-5
Targeted transgene insertion into human chromosomes by adeno-associated virus vectors
Nat Biotechnol. 2002 Jul; 20 (7):735-8
Mutational analysis of the tyrosine kinome in colorectal cancers
Science. 2003 May 9; 300 (5621): 949
Facile methods for generating human somatic cell gene knockouts using recombinant adeno-associated viruses
Nucleic Acids Res. 2004 Jan 2; 32(1): e3
Mutational analysis of the tyrosine phosphatome in colorectal cancers
Science. 2004 May 21; 304 (5674): 1164-6
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukaemia
Cancer Res. 2004 Dec 15; 64 (24): 8816-20
Improved methods for the generation of human gene knockout and knock-in cell lines
Nucleic Acids Res. 2005 Oct 7; 33(18): e158
Colorectal cancer: mutations in a signalling pathway
Nature. 2005 Aug 11; 436(7052):792
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti-EGFR treatment in colorectal cancer: a cohort study
Lancet Oncol. 2005 May; 6(5): 279-86
Somatic mutation of EGFR catalytic domain and treatment with gefitinib in colorectal cancer
Ann Oncol. 2005 Nov; 16(11): 1848-9. Epub 2005 Jul 12
Kinase mutations in cancer: chinks in the enemy’s armour?
Curr Opin Oncol. 2006 Jan; 18(1): 69-76
Oncogenic activation of the RAS/RAF signalling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies
Cancer Res. 2007 Mar 15; 67(6): 2643-8
Genetic targeting of the kinase activity of the Met receptor in cancer cells
Proc Natl Acad Sci U S A. 2007 Jul 3; 104(27): 11412-7. Epub 2007 Jun 26
Knock-in of oncogenic Kras does not transform mouse somatic cells but triggers a transcriptional response that classifies human cancers
Cancer Res. 2007 Sep 15; 67(18): 8468-76
Genomics landscapes for cancer:pProspects for targeted therapies
Pharmacogenomics. 2007; 8 (12): 1629-1633
Wild-Type BRAF Is Required for Response to Panitumumab and Cetuximab in Metastatic Colorectal Cancer
10.1200/JCO.2008.18.0786